Background/Aims: Atherosclerosis is a chronic inflammatory disease. Intracellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1), and monocyte chemoattractant protein-1 (MCP-1) play important roles in inflammatory processes. P38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB signaling regulate ICAM-1, VCAM-1, and MCP-1 expression. Angiotensin (Ang) II upregulates ICAM-1, VCAM-1, and MCP-1 expression through the P38 MAPK and NF-κB pathways. Ang-(1-7) may oppose the actions of Ang II. We investigated whether Ang-(1-7) prevents Ang II-induced ICAM-1, VCAM-1, and MCP-1 expression in human umbilical vein endothelial cells (HUVECs). Methods: ICAM-1, VCAM-1, and MCP-1 expression was estimated by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA); P38, NF-κB, and p-IκB-α expression was estimated by western blotting. Results: Ang-(1-7) inhibited Ang II-induced ICAM-1, VCAM-1, and MCP-1 expression and secretion in HUVECs. Ang II sharply increased P38 MAPK phosphorylation, which was inhibited by pretreatment with Ang- (1-7) . Moreover, Ang-(1-7) significantly inhibited Ang II-induced IκB-α phosphorylation and NF-κB P65 nuclear translocation. The MAS receptor antagonist A-779 abolished the suppressive effects of Ang-(1-7). Conclusion: Ang-(1-7) attenuates Ang II-induced ICAM-1, VCAM-1, and MCP-1 expression via the MAs receptor by suppressing the P38 and NF-κB pathways in HUVECs. Ang-(1-7) might delay the progression of inflammatory diseases, including atherosclerosis.
Introduction
Atherosclerotic cardiovascular diseases such as coronary heart disease (CHD), peripheral artery disease, and carotid artery stenosis are leading causes of morbidity and mortality. Atherosclerosis is a chronic inflammatory disease [1] . Monocytes adhere to vascular endothelial cells and transform into macrophages during atherosclerosis prophase [2] . Intracellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1), and monocyte chemoattractant protein-1 (MCP-1) play important roles in this process. ICAM-1 and VCAM-1, which are adhesion molecules, facilitate firm adhesion of leukocytes to endothelial cells [3] . MCP-1 is involved in leukocyte rolling and cross-endothelium migration [4] . ICAM-1, VCAM-1, and MCP-1 have been used as noninvasive markers for the evaluation of endothelial dysfunction and modification in patients with CHD [5] . Thus, downregulating the expression of ICAM-1, VCAM-1, and MCP-1 may retard the development of atherosclerosis.
P38 mitogen-activated protein kinase (MAPK) is involved in directing cellular responses to various stimuli and in the regulation of cellular processes such as inflammation, proliferation, and cell survival [6, 7] . The transcription factor, nuclear factor kappa B (NF-κB), is also involved in cellular responses to various stimuli, including inflammatory diseases such as atherosclerosis [8] . P38 MAPK and NF-κB promote the expression of genes encoding cytokines, the adhesion molecules ICAM-1, VCAM-1, and the chemoattractant protein MCP-1 [9, 10] .
Angiotensin (Ang) II is an important biologically active peptide of the rennin-angiotensin system (RAS). Ang II induces numerous biological effects such as vasoconstriction, increased myocardial contractility, cell proliferation, and water-sodium retention [11, 12] . Recent studies have shown that Ang II increases ICAM-1 and VCAM-1 expression in human umbilical vein endothelial cells (HUVECs) and MCP-1 expression in vascular smooth muscle cells through the P38 MAPK and NF-κB pathways [13] [14] [15] [16] .
Ang-(1-7) is a novel component of RAS that is synthesized from Ang I and Ang II by the catalytic action of enzymes. Ang-(1-7) exerts its biological effects through the autospecific acceptor MAS. Recent studies have demonstrated that Ang-(1-7) can antagonize the abovementioned physiological effects of Ang II [17, 18] . Accordingly, in contrast to Ang II, Ang-(1-7) induces relaxation of blood vessels, and it inhibits smooth muscle cell growth. Moreover, Ang-(1-7) has anti-atherosclerotic and antiproliferative effects [19] [20] [21] . Wang et al. [22] recently reported that Ang-(1-7) prevents Ang II-induced VCAM-1 and MCP-1 expression by inhibiting lectin-like oxidized low-density lipoprotein receptor (LOX)-1 in HUVECs. However, to the best of our knowledge, whether Ang-(1-7) prevents the Ang II-induced expression of ICAM-1, VCAM-1, and MCP-1 through the P38 MAPK and NF-κB pathways in HUVECs has not been investigated.
In this study, we investigated the effects of Ang-(1-7) on Ang II-induced ICAM-1, VCAM-1 and MCP-1 expression in HUVECs and its possible molecular relationship with the P38 MAPK and NF-κB pathways. Our results revealed that Ang (1-7) attenuates Ang II-induced ICAM-1, VCAM-1, and MCP-1 expression via the MAS receptor through suppression of the P38 MAPK and NF-κB pathways in HUVECs. These results might provide the basis for the treatment of clinical cardiovascular diseases.
Materials and Methods

Reagents
Ang II, Ang-(1-7), SB203580, and pyrrolidine dithiocarbamate (PDTC) were purchased from Sigma Aldrich (St. Louis, MO, USA). A-779 was purchased from the American Peptide Company (Sunnyvale, CA, USA). ICAM-1, VCAM-1, and MCP-1 enzyme-linked immunosorbent assay (ELISA) kits were purchased from the DA KE WEI company (Shenzhen, China). Antibodies against, P38 MAPK, phopho-P38, NF-κB p65, IκB-α, phosphor-IκB-α, proliferating cell nuclear antigen (PCNA), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Abcam (Cambridge, UK).
ELISA
The levels of MCP-1, VCAM-1, and ICAM-1 in the culture supernatant were estimated by ELISA according to the manufacturer's protocol. Briefly, 100 µL of standard cytokine or culture supernatant was added to each well and incubated for 60 min at 37 °C. The cells were then incubated for 60 min with 100 µL of 1× biotin and for 60 min with 100 µL of 1× horseradish peroxidase (HRP). After every incubation, each well was washed five times with wash buffer. Finally, 100 µL of stop solution was added to each well to terminate the reaction, and the plates were incubated in the dark for 30 min with 100 µL of 3,3′,5,5′-tetramethylbenzidine at 37 °C. The optical density of each well was determined using a microplate reader at 450 nm within 30 min. A standard curve for each cytokine was generated. On the basis of this standard curve, linear regression analysis was performed using the Microcal Origin 6.0 software.
Western blot analyses
Briefly, after treatment, 1 × 10 6 HUVECs were harvested, and protein extracts were prepared. For western blot analyses, 50 µg of protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidene fluoride membranes (Millipore Inc., Billerica, MA, USA). The mem branes were then blocked for 1 h in 3% non-fat dry milk, and incubated at 4 °C overnight with anti-mouse monoclonal PCNA, GAPDH (1:1,000 dilution; Santa Cruz Biotechnolo gy, Santa Cruz, CA, USA), P38, phopho-P38, NF-κB p65, phosphor-IκB-α antibodies (1:1,000 dilution; Cell Signaling, Boston, MA, USA). The membranes were then incubated with anti-mouse or anti-rabbit secondary antibody (1:10,000 dilution; Santa Cruz Biotechnolo gy, Santa Cruz, CA, USA) for 1 h. The proteins were visualized using a chemiluminescence detection system (Amersham, Poole, UK), and the signal intensities were analyzed using a Gel Imaging System (Bio-Rad). The relative protein expression level was determined by normalizing the values obtained to that of GAPDH.
Statistical analysis
All values are expressed as means ± standard deviations (SD). Student's t-test was used to analyze differences between two groups. Analysis of variance (ANOVA) was used to compare the means of three or 
Results
Isolation and identification of HUVECs
Immunofluorescence staining of Von Willebrand factor (vWF), which is specifically expressed in blood vessel endothelial cells, was performed to identify HUVECs. The results revealed that nearly 100% of the isolated cells were vWF-positive (Fig. 1 ).
Ang-(1-7) attenuates Ang II-induced expression of ICAM-1, VCAM-1, and MCP-1 in HUVECs
To evaluate effects of Ang-(1-7) on Ang II-induced expression of ICAM-1, VCAM-1, and MCP-1 in HUVECs, the cells were pre-treated with 1000 nM Ang-(1-7) for 30 min and then stimulated with 100 nM Ang II for 6 h. Culture supernatants were collected, and the levels of ICAM-1, VCAM-1, and MCP-1 were determined by ELISA. Meanwhile, the HUVECs were harvested, and the mRNA levels of ICAM-1, VCAM-1, and MCP-1 were estimated by real-time PCR. Ang II treatment resulted in marked increase in ICAM-1, VCAM-1, and MCP-1 mRNA expression and secretion, compared with the control. However, pretreatment with Ang-(1-7) inhibited ICAM-1, VCAM-1, and MCP-1 mRNA expression and secretion, compared with Ang II treatment alone. Pretreatment with A779 blocked the Ang-(1-7)-mediated inhibition of Ang II-induced expression of ICAM-1, VCAM-1, and MCP-1 in HUVECs (Fig. 2) .
Ang-(1-7) inhibits Ang II-induced P38 MAPK phosphorylation in HUVECs
The P38 MAPK signaling pathway plays an important role in the regulation of inflammation. Therefore, we investigated the effect of Ang-(1-7) on the activation of phospho-P38. The phosphorylation level of P38 MAPK increased significantly upon treatment with Ang II. The phosphorylation level decreased upon pretreatment with Ang- (1-7) . However, treatment with A779 significantly inhibited Ang-(1-7)-induced reduction in the level of phospho-P38 (Fig. 3) .
Ang-(1-7) inhibits Ang II-induced IκB-α phosphorylation and NF-κB translocation in HUVECs
The NF-κB pathway is a key mediator of inflammation. Therefore, we estimated the effect of Ang-(1-7) on the activation of the Ang II-induced NF-κB pathway. As shown in Fig   Fig. 1 . Immunofluorescence staining of Von Willebrand factor (vWF) was performed to identify human umbilical vein endothelial cells (HUVECs) cultured in vitro. The panels show normal cultured HUVECs (A) and immunostaining of vWF (B). Nearly 100% of the isolated cells were vWF-positive.
Effects of SB203580 and PDTC on Ang II-induced expression of ICAM-1, VCAM-1, and MCP-1 in HUVECs
A recent study demonstrated that Ang II increases ICAM-1 and VCAM-1 expression in HUVECs and MCP-1 expression in vascular smooth muscle cells through the P38 MAPK and 
plus 1000 nM Ang-(1-7) for 30 min before being incubated with 100 nM Ang II for another 6 h. A, C, and E. mRNA expression of ICAM-1, VCAM-1, and MCP-1 was measured by real-time polymerase chain reaction (PCR). B, D, and F. Culture supernatants were collected, and the secretion levels of ICAM-1, VCAM-1, and MCP-1 were determined by enzyme-linked immunosorbent assay (ELISA). Data are presented as the means ± standard deviation (SD) of three independent experiments. *P < 0.05 compared with the control group; # P < 0.05 compared with the Ang II group; HUVECs were incubated with 100 nM Ang II alone for 30 min. Furthermore, HUVECs were pretreated with 1000 nM Ang-(1-7) or 1000 nM A-779 (MAS receptor antagonist) plus 1000 nM Ang-(1-7) for 30 min before being incubated with 100 nM Ang II for another 30 min. The expression of nuclear factor (NF)-κB and p-IκB-α was measured by western blotting. Data are presented as the means ± SD of three independent experiments. *P < 0.05 compared with the control group; # P < 0.05 compared with the Ang II group;
Discussion
In recent years, it has been generally accepted that atherosclerosis is a chronic hyperplasia inflammatory process. ICAM-1 and VCAM-1 are members of the immunoglobulin superfamily, and they are mainly expressed in vascular endothelial cells, lymph cells, and monocytes. MCP-1 is involved in leukocyte rolling and cross-endothelium migration. In recent years, several studies have suggested that the expression of ICAM-1, VCAM-1, and MCP-1 is correlated with the development of atherosclerosis. In addition, P38 MAPK and NF-κB signaling have been shown to be involved in inflammatory process, especially in the regulation of ICAM-1, VCAM-1 and MCP-1 expression.
Ang II is an important biologically active peptide of RAS. Previous in vivo and in vitro studies have suggested that Ang II upregulates the expression of ICAM-1, VCAM-1, and MCP-1 [23, 24] . Recently, it was reported that Ang II increases the expression of ICAM-1 and VCAM-1 through P38 MAPK and NF-κB signaling in HUVECs. Moreover, Ang II-mediated activation of the P38 MAPK pathway is not involved in the activation of NF-κB. In addition, Ang II upregulates the expression of MCP-1 through P38 MAPK and NF-κB signaling in vascular smooth muscle cells. In this study, we incubated HUVECs with 100 nM Ang II, and the expression levels of ICAM-1, VCAM-1, and MCP-1 increased significantly compared with the control (P < 0.05). When the HUVECs were pretreated with SB203580 or PDTC, the effect of Ang II on the expression of ICAM-1, VCAM-1, and MCP-1 was inhibited. Together, these results suggest that Ang II upregulates the expression of ICAM-1 and VCAM-1 through P38 MAPK and NF-κB signaling in HUVECs. This finding is consistent with the results of some previous reports [13] [14] [15] [16] . Our findings also suggest that Ang II increases MCP-1 expression through P38 MAPK and NF-κB signaling in HUVECs. To the best of our knowledge, this effect of Ang II has not been reported previously.
The heptapeptide Ang-(1-7) is an independent member of RAS, and it is produced directly from Ang II by the action of the recently discovered carboxypeptidase angiotensinconverting enzyme 2. Alternatively, Ang I can be converted by a neutral endopeptidase to Ang-(1-7). Initially, it was believed that Ang-(1-7) was the non-active metabolite of RAS. Subsequently, many studies have demonstrated that Ang-(1-7) can antagonize the biological effects of Ang II. Zhang et al. [25] demonstrated that Ang-(1-7) inhibits Ang II-induced SMC proliferation and migration through negative modulation of Ang II-induced ERK1/2 activity. Yang et al. [26] reported that Ang-(1-7) inhibited atherosclerotic lesion formation by targeting vascular smooth muscle cells and that a large dose of Ang-(1-7) may stabilize mature plaque by targeting macrophages in ApoE(-/-) mice. Recently, our laboratory demonstrated that Ang-(1-7) improves reverse cholesterol transport by improving the expression of adenosine triphosphate-binding cassette transporter A1 and adenosine triphosphate-binding cassette transporter G1, which protect against atherosclerosis [27, 28] . However, whether Ang-(1-7) attenuates Ang II-induced ICAM-1, VCAM-1, and MCP-1 expression through P38 MAPK and NF-κB pathways in HUVECs was unclear. In this study, we first examined the effect of Ang-(1-7) on ICAM-1, VCAM-1, and MCP-1 expression. We found that Ang-(1-7) inhibited Ang II-induced mRNA and secretion of ICAM-1, VCAM-1, and MCP-1 in HUVECs, which suggests a possible beneficial effect of Ang-(1-7) via the attenuation of HUVECs activation and inflammation. Therefore, Ang-(1-7) might delay the progression of inflammatory diseases.
In order to further elucidate the mechanisms underlying the inhibitory effect of Ang-(1-7) on the expression of ICAM-1, VCAM-1, and MCP-1 in HUVECs, we investigated the effect of Ang-(1-7) on the activation (phosphorylation) of P38 MAPK induced by Ang II in HUVECs. The results revealed that Ang II sharply increases the phosphorylation of P38 MAPK, which was, in turn, inhibited by pretreatment with Ang- (1-7) . Our results suggested that the Ang-(1-7)-mediated attenuation of inflammation is associated with the downregulation of P38 MAPK phosphorylation.
NF-κB is clearly one of the most important regulators of inflammation. The expression of ICAM-1, VCAM-1, and MCP-1 is mediated by NF-κB. NF-κB dimers are rendered inactive in the cytosol by inhibitory proteins of the IκB family in unstimulated cells [29] . The crucial step in NF-κB activation is IκB phosphorylation, which occurs because of activation of the IκB kinase complex. The phosphorylation of inhibitory IκB proteins triggers their ubiquitination and subsequent proteasomal degradation, followed by the release and nuclear translocation of active NF-κB [30] [31] [32] . We examined whether Ang-(1-7)-mediated signaling pathways modulate NF-κB signaling to study the molecular mechanisms underlying the anti-inflammatory effect of Ang-(1-7). Incubation of HUVECs with Ang II caused marked cytosolic phosphorylation of IκB-α and NF-κB p65 translocation into the nucleus, but pretreatment with Ang-(1-7) significantly inhibited IκB-α phosphorylation and NF-κB p65 nuclear translocation. These results indicated that Ang-(1-7) suppressed Ang II-induced inflammatory responses by inhibiting Ang II-induced IκB-α phosphorylation and NF-κB p65 nuclear translocation in HUVECs.
Many of the cardiovascular effects of Ang-(1-7) are completely blocked by the selective Ang-(1-7) antagonist, A-779, suggesting that the effects of Ang-(1-7) are mediated by a specific receptor sensitive to A-779. Recently, Santos et al. [33] reported that Ang-(1-7) is an endogenous ligand for the G-protein-coupled receptor, MAS. Specific binding of In conclusion, our data suggest that Ang-(1-7) inhibits Ang II-induced expression of ICAM-1, VCAM-1, and MCP-1 through P38 MAPK-and NF-κB-dependent signaling in HUVECs. Moreover, the beneficial effects of Ang-(1-7) are reversed by A779. Thus, these results suggest that the Ang-(1-7)/MAS receptor axis is an important mechanism that reverses the inflammatory cascades involved in atherosclerosis, and activation of this pathway may be a novel therapeutic approach for the treatment of atherosclerosis.
